Previous 10 | Next 10 |
2023-10-06 15:00:00 ET More on the stock market The U.S. Government Shutdown: Not A Crisis SPY Madness: 'Magnificent Seven' Stocks Up An Average 95% YTD While The Average Stock Is Down More Shades Of 2007 Buy-rated dividend stocks for volatility and high rate...
2023-10-05 05:30:00 ET More on Markets As 10-year Treasury yield pushes higher, Wolfe Research calls for 5% by year end Correction could be coming for mega caps - Wells Fargo Berenberg: Get defensive with healthcare, utilities and telecoms BlackRock is overwe...
2023-09-11 15:22:28 ET More on Bicycle Therapeutics Seeking Alpha’s Quant Rating on Bicycle Therapeutics Historical earnings data for Bicycle Therapeutics Financial information for Bicycle Therapeutics Bicycle Therapeutics: Decent Upside Opportunity, M...
2023-09-11 14:19:40 ET Shares of Bicycle Therapeutics (NASDAQ: BCYC) were up 9% as of 1:30 p.m. ET on Monday after the healthcare stock climbed as high as 10.4% earlier in the day. The company's shares are still down more than 8% so far this year. The clinical-stage biotec...
Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer Conference call and webca...
Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st ...
2023-08-03 13:56:13 ET Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q2 GAAP EPS of -$1.41 misses by $0.39 . Revenue of $11.4M (+160.3% Y/Y) misses by $1.52M . Cash and cash equivalents were $340.4 million as of June 30, 2023, compared to $339.2 million ...
Continued progress across pipeline, including advancing BT8009, BT5528, and BT7480 in ongoing clinical trials; clinical and regulatory updates remain on track for BT8009 in 2H23 Entered into strategic collaborations with Novartis, Bayer, and broadened an ongoing collaboration with DKFZ in...
2023-07-31 19:07:20 ET Summary Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-stage oncology assets that have achieved some results of interest in urothelial / ovarian cancers. ...
Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the closing on Monday, July 17, 2023 of its underwritten public offering of 6,117,...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...
Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the second half of 2027 Supports ongoing advancement of pipeline with multiple clinical-...